LMNB1 and LMNB2 as Prognostic Risk Factors in Hepatocellular Carcinoma: Therapeutic Potential of GSK461364 via Downregulation of LMNB1 and LMNB2 Expression
LMNB1 and LMNB2 are prognostic factors for HCC. GSK461364 is a novel therapeutic candidate for HCC, with anti-HCC effects associated with LMNB1/2 suppression.
Authors
- Wenhao Suo (ORCID: https://orcid.org/0000-0002-3106-2605)
- Qing Peng (ORCID: https://orcid.org/0000-0002-2238-8400)
- Mingxin Pan (ORCID: https://orcid.org/0000-0002-3979-5571)
- Hui Yong (ORCID: https://orcid.org/0000-0003-3191-0835)
- Rongxia Li (ORCID: https://orcid.org/0000-0003-0664-4803)
- Xin Kang (ORCID: https://orcid.org/0000-0002-9758-9100)
- Binhui Li
- Zizhong Hu (ORCID: https://orcid.org/0000-0001-6289-1804)
- Yingqi Zhou
- Wanren Yang
- Jia Yao (ORCID: https://orcid.org/0000-0003-0716-000X)
- Botian Ouyang
Institutions
- Third Affiliated Hospital of Southern Medical University (CN)
- Longgang Central Hospital (CN)
- Qinghai No.3 People's Hospital (CN)
- Chinese University of Hong Kong, Shenzhen (CN)
- Zhujiang Hospital (CN)
- University of Hong Kong - Shenzhen Hospital (CN)
- Qinghai Provincial Peoples Hospital (CN)
- Shenzhen Second People's Hospital (CN)
- Southern Medical University (CN)
Publication Details
- Journal
- Recent Patents on Anti-Cancer Drug Discovery
- Published
- 2025-08-04
- DOI
- https://doi.org/10.2174/0115748928375684250716120144
- Primary Topic
- Cancer, Hypoxia, and Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 0.00